These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 23494648)

  • 1. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
    Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
    Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    Agostini S; Mancuso R; Citterio LA; Caputo D; Oreni L; Nuzzi R; Pasanisi MB; Rovaris M; Clerici M
    Neurobiol Dis; 2024 Oct; 200():106648. PubMed ID: 39181188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential microRNA expression in blood in multiple sclerosis.
    Søndergaard HB; Hesse D; Krakauer M; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1849-57. PubMed ID: 23773985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis.
    Selmaj I; Cichalewska M; Namiecinska M; Galazka G; Horzelski W; Selmaj KW; Mycko MP
    Ann Neurol; 2017 May; 81(5):703-717. PubMed ID: 28411393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Vistbakka J; Elovaara I; Lehtimäki T; Hagman S
    Mult Scler; 2017 Mar; 23(3):403-412. PubMed ID: 27246141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases.
    Sharaf-Eldin WE; Kishk NA; Gad YZ; Hassan H; Ali MAM; Zaki MS; Mohamed MR; Essawi ML
    J Neurol Sci; 2017 Dec; 383():188-198. PubMed ID: 29246612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.
    Keller A; Leidinger P; Steinmeyer F; Stähler C; Franke A; Hemmrich-Stanisak G; Kappel A; Wright I; Dörr J; Paul F; Diem R; Tocariu-Krick B; Meder B; Backes C; Meese E; Ruprecht K
    Mult Scler; 2014 Mar; 20(3):295-303. PubMed ID: 23836875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.
    Yang G; Yang L; Wang W; Wang J; Wang J; Xu Z
    Gene; 2015 May; 562(1):138-44. PubMed ID: 25725128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of potential microRNA biomarkers for multiple sclerosis.
    Al-Temaimi R; Alshammari N; Alroughani R
    Exp Mol Pathol; 2024 Jun; 137():104903. PubMed ID: 38772208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis.
    Takahashi I; Hama Y; Matsushima M; Hirotani M; Kano T; Hohzen H; Yabe I; Utsumi J; Sasaki H
    Mol Brain; 2015 Oct; 8(1):67. PubMed ID: 26497046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.
    Keller A; Leidinger P; Meese E; Haas J; Backes C; Rasche L; Behrens JR; Pfuhl C; Wakonig K; Gieß RM; Jarius S; Meder B; Bellmann-Strobl J; Paul F; Pache FC; Ruprecht K
    J Neuroinflammation; 2015 Oct; 12():196. PubMed ID: 26521232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
    Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
    Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
    [No Abstract]   [Full Text] [Related]  

  • 15. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
    Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
    J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplex Analysis of Cerebrospinal Fluid and Serum Exosomes MicroRNAs of Untreated Relapsing Remitting Multiple Sclerosis (RRMS) and Proposing Noninvasive Diagnostic Biomarkers.
    Mohammadinasr M; Montazersaheb S; Molavi O; Kahroba H; Talebi M; Ayromlou H; Hejazi MS
    Neuromolecular Med; 2023 Sep; 25(3):402-414. PubMed ID: 37020076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells.
    Sanders KA; Benton MC; Lea RA; Maltby VE; Agland S; Griffin N; Scott RJ; Tajouri L; Lechner-Scott J
    Clin Epigenetics; 2016; 8(1):87. PubMed ID: 27570566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.